In a research report issued today, Piper Jaffray analyst Joshua Schimmer reiterated a Neutral rating on ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) with a price target of …
On April 29, Joshua Schimmer of Piper Jaffray released a report highlighting several biopharmaceutical companies tackling Sickle Cell Disease, or SCD. The hereditary blood disorder …
In a research report released today, Piper Jaffray analyst Joshua Schimmer reiterated an Overweight rating on shares of Biogen Inc (NASDAQ:BIIB), but slightly reduced the …
In a research report published today, Piper Jaffray analyst Joshua Schimmer reiterated an Overweight rating on GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) with a price …
On Monday, Uniqure NV (NASDAQ:QURE) and Bristol-Myers Squibb Co (NYSE:BMY) announced an exclusive strategic collaboration in which the agreement gives Bristol-Myers “exclusive …
Uniqure NV (NASDAQ:QURE) shares were on the rise Monday after the company announced a landmark platform deal with Bristol-Myers Squibb Co (NYSE:BMY) which will include the company's proprietary …
In a research report published Monday, Piper Jaffray analyst Joshua Schimmer maintained an Overweight rating on Insmed Incorporated (NASDAQ:INSM) with a $51 price target, …
In a research report published Friday, Piper Jaffray analyst Joshua Schimmer reiterated an Overweight rating on Celgene Corporation (NASDAQ:CELG) and raised the price …
In a research report issued today, Piper Jaffray analyst Joshua Schimmer reiterated a Neutral rating on Pharmacyclics, Inc. (NASDAQ:PCYC) with a price target of …
In a research report issued Monday, Piper Jaffray analyst Joshua Schimmer reiterated a Neutral rating on ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) with a $68 price …
